Single Asset
One therapeutic, device, or test. Value is the asset. If the lead fails, the company is over.
Strategic Shape Diagnostic
What shape is your company?
7 minutes. 7 archetypes. Find out how your company actually transacts — and what to say in your next pitch.
Start the Diagnostic
$49 · Report delivered instantly
The Problem
Most founders describe their company wrong to investors.
27% of life sciences companies claim to be platforms. 8% have the evidence. The gap costs $176M in median deal value — because the wrong shape triggers the wrong comps, the wrong counterparties, and the wrong term structures.
If you can’t name your shape, you can’t control the conversation.
Seven Archetypes
Every life sciences company is one of these.
Asset-Led, Platform Aspiration
One meaningfully advanced program plus a claimed breadth that is not yet evidenced. The most common shape across all four modalities globally, and the most consequential misclassification.
True Platform
The technology generates distinct assets or products. Value survives failure of any one program.
Enabling Technology
Value accrues by improving someone else's product. Delivery and formulation in biopharma; components and subsystems in device; sample prep, chemistry, and licensed platforms in diagnostics.
Tool / Research Product
Sells to researchers, labs, or pharma. Revenue possible without clinical clearance.
Instrument plus Consumable
A placed instrument or reader plus a required recurring consumable. No biopharma analog. Distinct economics, distinct acquirer set, distinct valuation logic.
Service Line
Delivered as a service through an owned lab or facility rather than sold as a product. CLIA labs, imaging services, interpretation services. Acquirer set is entirely distinct from tools companies.
How It Works
Three steps. No ambiguity.
01
Answer 22 questions
Modality-specific. Geography-aware. Takes about 7 minutes.
02
Get classified
6 scores, decision cascade, confidence band. Free.
03
Unlock the report
9 sections. Contradictions. Deal economics. $49.
What You Get
Nine sections. Each one is a decision.
01
Shape & Evidence
Your archetype, the six classification scores, and the signals that determined each one.
02
Contradictions
Where what you say diverges from what the evidence shows. Severity-ranked, resolution paths included.
03
How Shape Transacts
The deal structures, term ranges, and counterparty types that actually close for your archetype.
04
What Doesn’t Transact
Structures and narratives your shape cannot support. What to stop pitching.
05
Three Decisions
The three highest-leverage decisions available to your company given its current shape.
06
How to Describe the Company
Language that matches how investors and acquirers actually categorize you. Replace the deck.
07
Shape Economics
Median upfront, milestone structure, and royalty ranges for your archetype, modality, and geography.
08
Acquirer Readiness
Which capital classes acquire your shape, what they look for, and where you stand against those criteria.
09
Capital Strategy
How your shape affects your next raise, your dilution profile, and when a transaction should happen.
The Confrontation
The diagnostic shows you what investors already see.
What the founder says
“We’re a platform company.”
The deck describes a multi-asset pipeline, cross-indication versatility, and a discovery engine that generates new programs.
What the evidence shows
ALPA — Asset-Led, Platform Aspiration
One program past lead optimization. Two at target ID. IP covers the lead only. 87% of next-round budget allocated to one program. No third-party access to the platform.
The ALPA is the most common shape in life sciences — and the most common misclassification. It transacts differently than a platform. Different term structures. Different counterparties. Different economics. The diagnostic tells you which one you actually are.
Pricing
Classification is free. The report is $49.
Classification
Free
- ✓Primary archetype classification
- ✓6 classification scores
- ✓Confidence band
- ✓Frequency distribution
- ✓Shareable result card
Full Report
$49
- ✓Everything in Free
- ✓9 full report sections
- ✓Contradiction analysis with severity ranking
- ✓Investor perception mapping
- ✓Counterfactual deal economics
- ✓Three highest-leverage decisions
- ✓Shape-matched description language
One-time purchase. Instant delivery.
Questions
Frequently asked
What modalities are covered?
Biotech, medical device, diagnostics, and convergent (companies spanning more than one modality). The intake adapts to your modality — a diagnostics company sees different questions than a biotech.
How long does it take?
The intake is 22 questions, typically completed in 7 minutes. Classification is instant. The full report is delivered immediately after purchase.
What happens after I get classified?
You see your archetype, scores, confidence band, and frequency distribution for free. From there you can purchase the full report ($49) or share your result card.
Is my data shared?
No. Your responses are used only to generate your classification and report. We do not share individual company data with third parties.
Can I retake the diagnostic?
Yes. Companies evolve. If your pipeline, IP, or team composition changes materially, retaking the diagnostic will reflect the new reality.
What is a "shape"?
Shape is our term for how a company actually transacts — not what it claims to be, but how the evidence positions it in the eyes of acquirers, licensors, and investors. Shape determines your deal economics, your counterparty set, and the structures available to you.
Your shape determines your deal economics.
Find out what yours is.
Start the Diagnostic
Free classification · $49 full report